Mazelsky Purchases XRAY Shares as Institutional Activity Heats Up

Jonathan Jay Mazelsky, an insider at XRAY, purchased 10,000 shares of the company on June 12, 2026. The shares were bought at an average price of $10.14, amounting to a total transaction value of $101,400. This purchase is not part of a pre-planned trading program.

Other Institutional Activity in XRAY

Institutional activity around XRAY has been robust. BlackRock, Inc. increased its position by adding 547,312 shares, bringing its total to 19,251,869 shares valued at approximately $223.3 million. First Eagle Investment Management, LLC also grew its holdings by 487,378 shares, ending with 15,127,933 shares worth about $175.5 million. Fuller & Thaler Asset Management, Inc. added 287,008 shares, totaling 12,792,518 shares valued at roughly $148.4 million. Meanwhile, Vanguard Portfolio Management LLC and Southpoint Capital Advisors LP both maintained significant positions, holding 10,530,746 and 10,000,000 shares, respectively.

XRAY Stock Snapshot

Shares of XRAY are trading around $10.36. The stock has attracted attention due to recent insider and institutional activity. XRAY's market dynamics are influenced by these movements, as well as its performance in the broader market.

Insider Buying and Selling at XRAY

In addition to Mazelsky's purchase, several other insiders have been active. On June 15, 2026, Brian Gladden bought 9,985 shares at $10.02 each. On June 12, Brian McKeon bought 10,000 shares at $10.12. Betsy Holden made two purchases: 10,086 shares at $9.88 on June 11 and 22,822 shares on June 3. Michael Barber also bought 15,175 shares at $9.89 on June 11.

Analysts Set New Price Targets

Analysts have mixed views on XRAY. On June 4, 2026, Barclays maintained a 'sell' rating with a $9.00 price target. UBS, on May 7, maintained a 'buy' rating with a $17.00 target. Citigroup initiated coverage with a 'sell' rating and a $10.00 target on April 15. Other firms like Mizuho and Barrington Research have maintained 'hold' and 'buy' ratings, respectively, with targets ranging from $13.00 to $17.00.

Bottom Line

The recent insider buying by Mazelsky and other insiders, coupled with significant institutional changes, underscores the dynamic interest in XRAY shares. Investors keep a close watch on such activities as they can indicate confidence in the company's future. However, as these are backward-looking reports, they may not fully reflect current positions or future intentions.